ArticleNature medicine2026
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.
Abstract read
In one paragraph
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Quantification of blood-based neurovascular unit biomarkers: an analytical platform comparison study.Resuscitation plus · 2026Article
- Sleep Disturbance Correlates with Cognitive Impairment Partly via Plasma p-Tau217: ADNI Cross-Sectional Evidence and P301L Mouse Mechanistic Observations.International journal of molecular sciences · 2026Article
- Article
- Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.The Lancet. Neurology · 2026Article
- Plasma p-Tau217 and SPECT-Based eZIS in Mild Cognitive Impairment: Concordance Analysis with Validation in an Amyloid PET Sub-Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Exploring longitudinal relationships among Alzheimer's disease biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Early detection of Alzheimer's disease with circular RNA from blood.Nature medicine · 2026Article
- Impact of Plasma p-tau181 on Cognition, Motor Phenotypes, and Disease Course in ALS.Annals of clinical and translational neurology · 2026Article
- Considerations in Alzheimer's Disease in Women.Current neurology and neuroscience reports · 2026Review
- Metal Binding to Tau Protein: Physiological and Pathological Relevance.Biochemistry · 2026Review
- Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease.bioRxiv : the preprint server for biology · 2026Article
- Genetic Associations with Temporal Modeling of Alzheimer's Disease Progression Supports a Novel Paradigm for Disease Risk.medRxiv : the preprint server for health sciences · 2026Article
- Recent advances in Alzheimer's disease: From molecular mechanisms to therapeutic strategies.Cell · 2026Review
- The countdown paradox: time-varying analysis of biomarker-clock age and symptom onset.medRxiv : the preprint server for health sciences · 2026Article
- Peripheral and Central miRNA Signatures in Alzheimer's Disease: Tissue-Specific Variability, Sex-Associated Differences, and Implications for Blood-Based Biomarkers.International journal of molecular sciences · 2026Review
- Biological plausibility of single-shell NODDI-DTI in non-demented older adults: associations with plasma biomarkers and follow-up cognition.Research square · 2026Article
- A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- A biomarker of Alzheimer's disease could be a useful diagnostic tool for other amyloidoses.Nature medicine · 2026Article
- Predicting Preclinical Cognitive Decline Using Plasma P-tau217 andmedRxiv : the preprint server for health sciences · 2026Article
- Continuum of Core 1 biomarkers in preclinical Alzheimer's disease.Alzheimer's research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Kellen K PetersenDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-3195-3456
Marta Milà-AlomàNorthern California Institute for Research and Education, San Francisco, CA, USA.
Yan LiDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-1340-6694
Lianlian DuWisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.ORCID http://orcid.org/0000-0002-1662-0883
Chengjie XiongKnight Alzheimer Disease Research Center, St. Louis, MO, USA.
Duygu TosunNorthern California Institute for Research and Education, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8644-7724
Benjamin SaefDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Ziad S SaadPrecision Measures, Johnson & Johnson, San Diego, CA, USA.
Lei Du-CunyAbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
Janaky CoomaraswamyTakeda Pharmaceutical Company Ltd., Cambridge, MA, USA.
Yulia MordashovaAbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
Carrie E RubelBiogen, Cambridge, MA, USA.
Emily A MeyersAlzheimer's Association, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-0886-6218
Leslie M ShawDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jeffrey L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-2192-1699
Nicholas J AshtonInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.ORCID http://orcid.org/0000-0003-3930-4354
Kyle FerberBiogen, Cambridge, MA, USA.
Gallen Triana-BaltzerPrecision Measures, Johnson & Johnson, San Diego, CA, USA.
Michael BarattaTakeda Pharmaceutical Company Ltd., Cambridge, MA, USA.
Erin G RosenbaughFoundation for the National Institutes of Health, North Bethesda, MD, USA.
Carlos CruchagaKnight Alzheimer Disease Research Center, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0276-2899
Eric McDadeDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-6764-3866
David M HoltzmanDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-3400-0856
John C MorrisDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
J Martin SabandalFoundation for the National Institutes of Health, North Bethesda, MD, USA.
Randall J BatemanDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-7729-1702
Anthony W BannonAbbVie, North Chicago, IL, USA.
William Z Potter
Suzanne E SchindlerDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA. schindlers@neuro.wustl.edu.ORCID http://orcid.org/0000-0002-1680-1465
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team
Funding
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7MCross Sectional and Longitudinal Racial Disparity in Molecular Biomarkers of Alzheimer DiseaseR01AG067505 · NIA · WASHINGTON UNIVERSITY · PI XIONG, CHENGJIE · 2020 to 2024
$14.7MStaging Alzheimer disease with blood-based biomarkersR01AG070941 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2021 to 2025
$4.3MProteomic characterization of aging cerebellumR01AG025350 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI SCHONEICH, CHRISTIAN · 2004 to 2008
$1.4MNIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS R01 AG025350NIA NIH HHS R01 AG067505U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) P01AG003991U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) P01AG026276U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) P30AG066444U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R01AG067505U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R01AG070941U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) RF1R01AG053550
Abstract
Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer's disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n = 258 and n = 345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted R
Indexed as
Alzheimer Diseasetau ProteinsAgedAged, 80 and overAge of OnsetAmyloid beta-PeptidesBiomarkersFemaleHumansMalePhosphorylationPositron-Emission TomographyAmyloid beta-PeptidesBiomarkerstau Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.